VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 355 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2013. The put-call ratio across all filers is 0.61 and the average weighting 1.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2016 | $111,000 | +20.7% | 4,525 | 0.0% | 0.00% | – |
Q2 2016 | $92,000 | -95.6% | 4,525 | -94.3% | 0.00% | -100.0% |
Q1 2016 | $2,104,000 | -84.5% | 80,000 | -40.0% | 0.00% | -85.7% |
Q4 2015 | $13,561,000 | -94.2% | 133,405 | -89.8% | 0.01% | -94.4% |
Q3 2015 | $233,784,000 | -32.2% | 1,310,597 | -15.6% | 0.25% | -30.1% |
Q2 2015 | $344,854,000 | +27.2% | 1,552,350 | +13.7% | 0.36% | +29.1% |
Q1 2015 | $271,188,000 | -2.3% | 1,365,358 | -29.6% | 0.28% | -0.4% |
Q4 2014 | $277,636,000 | -3.7% | 1,940,019 | -11.7% | 0.28% | -2.8% |
Q3 2014 | $288,347,000 | +31.6% | 2,197,763 | +26.5% | 0.29% | +38.6% |
Q2 2014 | $219,181,000 | -12.1% | 1,737,877 | -8.1% | 0.21% | -15.2% |
Q1 2014 | $249,378,000 | +7.4% | 1,891,662 | -4.4% | 0.24% | +9.4% |
Q4 2013 | $232,273,000 | +5.7% | 1,978,482 | -6.1% | 0.22% | +0.9% |
Q3 2013 | $219,719,000 | +34.1% | 2,105,992 | +10.7% | 0.22% | +28.5% |
Q2 2013 | $163,818,000 | – | 1,903,094 | – | 0.17% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |